Progress of Research on Immune-related Pneumonia in Non-small Cell Lung Cancer
10.3971/j.issn.1000-8578.2023.23.0075
- VernacularTitle:非小细胞肺癌免疫相关性肺炎研究进展
- Author:
Tianming WANG
1
;
Liang ZHANG
;
Ying CHENG
Author Information
1. School of Traditional Chinese Medicine, Changchun University of Traditional Chinese Medicine, Changchun 130000, China
- Publication Type:Research Article
- Keywords:
Non-small cell lung cancer;
Immune checkpoint inhibitors;
Interstitial pneumonia;
Research progress
- From:
Cancer Research on Prevention and Treatment
2023;50(8):808-812
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immunotherapy has made a breakthrough in the field of non-small cell lung cancer, reshaping the pattern of lung cancer treatment. However, with the wide application of immunotherapy in clinical practice, immune-related adverse events have attracted increasing attention. Immune pneumonia, as one of the immune-related toxic side effects of greatest concern, affects the treatment process and curative effect and can be a threat to life in serious cases. Given that immune pneumonia has a complicated pathogenesis and diverse clinical manifestations, strengthening the understanding of immune pneumonia is urgently needed. The treatment of immune pneumonia is limited, and additional therapeutic medicines are still awaiting exploration. Therefore, this paper summarizes the progress of the research on immune pneumonia in the treatment of non-small cell lung cancer.
